Budigalimab
As of the edition of 20 October 2026, Budigalimab is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2030
- Kind
- Antibody
- Registered trials
- 27, 6 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Hormones; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 20 | 8 | 7 | 5 |
| Phase 2 | 5 | 0 | 4 | 1 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 27 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AbbVie | Lead sponsor of trials | 2013 to now |
| Trishula Therapeutics | Lead sponsor of trials | 2020 to now |